PAROXETINE Drug Patent Profile
✉ Email this page to a colleague
When do Paroxetine patents expire, and what generic alternatives are available?
Paroxetine is a drug marketed by Prinston Inc, Apotex Inc, Novitium Pharma, Aurobindo Pharma Usa, Cadila Pharms Ltd, Cspc Ouyi, Epic Pharma Llc, Lannett Co Inc, Lupin Ltd, Sciecure Pharma Inc, Apotex, Aurobindo Pharma, Chartwell Rx, Jubilant Generics, Mylan, Norvium Bioscience, Oxford Pharms, Roxane, Sun Pharm Inds Inc, Teva Pharms, Upsher Smith Labs, Yiling, Zydus Pharms Usa, and Actavis Labs Fl Inc. and is included in twenty-seven NDAs.
The generic ingredient in PAROXETINE is paroxetine mesylate. There are thirty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Paroxetine
A generic version of PAROXETINE was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PAROXETINE?
- What are the global sales for PAROXETINE?
- What is Average Wholesale Price for PAROXETINE?
Summary for PAROXETINE
| US Patents: | 0 |
| Applicants: | 24 |
| NDAs: | 27 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Clinical Trials: | 259 |
| Patent Applications: | 3,903 |
| Drug Prices: | Drug price information for PAROXETINE |
| Drug Sales Revenues: | Drug sales revenues for PAROXETINE |
| What excipients (inactive ingredients) are in PAROXETINE? | PAROXETINE excipients list |
| DailyMed Link: | PAROXETINE at DailyMed |
See drug prices for PAROXETINE
Recent Clinical Trials for PAROXETINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Cairo University | Phase 3 |
| AbbVie | Phase 4 |
Pharmacology for PAROXETINE
| Drug Class | Serotonin Reuptake Inhibitor |
| Mechanism of Action | Serotonin Uptake Inhibitors |
US Patents and Regulatory Information for PAROXETINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 075566-003 | Mar 8, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chartwell Rx | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 076618-004 | Aug 15, 2005 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Apotex | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 075356-003 | Jul 30, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 078902-004 | Mar 13, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
